-+ 0.00%
-+ 0.00%
-+ 0.00%

ASCENTAGE PHARMA’S LISAFTOCLAX GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR TREATMENT-NAÏVE CLL/SLL

Reuters·10/20/2026 23:30:00

Please log in to view news